Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma

Transactions of the American Ophthalmological Society

Volumn 103, Issue , 2005, Pages 337-367

  Tse, David T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN;

ADENOID CYSTIC CARCINOMA; ADULT; ALLELE; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FAST NEUTRON RADIATION; FEMALE; GAMMA KNIFE RADIOSURGERY; GENE LOSS; GENETIC ANALYSIS; GENOTYPE; HISTOLOGY; HUMAN; INTRAARTERIAL CYTOREDUCTIVE CHEMOTHERAPY; LACRIMAL GLAND; LOG RANK TEST; MALE; MICRODISSECTION; MICROSATELLITE MARKER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOID CYSTIC; EYE NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GENOTYPE; HUMANS; INJECTIONS, INTRA-ARTERIAL; LACRIMAL APPARATUS DISEASES; MAGNETIC RESONANCE IMAGING; MALE; MICRODISSECTION; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 29944440695     PISSN: 15456110     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Lee DA, Campbell RJ, Waller RR, et al. A clinicopathologic study of primary adenoid cystic carcinoma of the lacrimal gland. Ophthalmology 1985;92:128-134.
2. Henderson J W. Orbital Tumors. 2nd ed. New York: Decker; 1980:414-418.
3. Font RL, Gamel JW. Epithelial tumors of the lacrimal gland: an analysis of 265 cases. In: Jakobiec FA, ed. Ocular and Adnexal Tumors. Birmingham, Alabama: Aesculapius; 1978:787-805.
4. Font RL, Smith SL, Bryan RG. Malignant epithelial tumors of the lacrimal gland; a clinicopathologic study of 21 cases. Arch Ophthalmol 1998;116:613-616.
5. Font RL, Gamel JW. Adenoid cystic carcinoma of the lacrimal gland. A clinicopathologic study of 79 cases. In: Nicholson DH, ed. Ocular Pathology Update. New York: Masson Publishing; 1980:277-283.
6. Henderson JW. Adenoid cystic carcinoma of the lacrimal gland: Is there a cure? Trans Am Ophthalmol Soc 1987;85:312-314.
7. Byers RM, Berkeley RG, Luna M, et al. Combined therapeutic approach to malignant lacrimal gland tumors. Am J Ophthalmol 1975;79:53-55.
8. Wright JE, Stewart WB, Krohel GB. Clinical presentation and management of lacrimal gland tumours. Br J Ophthalmol 1979;63:600-606.
9. Gamel JW, Font RL. Adenoid cystic carcinoma of the lacrimal gland: the clinical significance of a basaloid histologic pattern. Hum Pathol 1982;13:219-225.
10. Wright JE. Factors affecting the survival of patients with lacrimal gland tumours. Can J Ophthalmol 1982;17:3-9.
11. Jakobiec FA. Discussion of Henderson JW. Adenoid cystic carcinoma of the lacrimal gland: Is there a cure? Trans Am Ophthalmol Soc 1987;85:314-317.
12. Saini JS, Mohan K, Khandalavala B. Primary radiotherapy in adenoid cystic carcinoma of the lacrimal gland. Orbit 1990;9:107-111.
13. Asikin Natanegara IAA, Koornneef L, Veenhof K, et al. An alternative approach for the management of adenocystic carcinoma of the lacrimal gland. Orbit 1990;9:101-105.
14. Polito E, Leccisotti A. Epithelial malignancies of the lacrimal gland: survival rates after extensive and conservative therapy. Ann Ophthalmol 1993;25:422-426.
15. Shields JA, Shields CL, Eagle RC Jr, et al. Adenoid cystic carcinoma of the lacrimal gland simulating a dermoid cyst in a 9-year-old boy. Arch Ophthalmol 1998;116:1673-1676.
16. Tyl JWM, Blank LECM, Koornneef L. Brachytherapy in orbital tumors. Ophthalmology 1997;104:1475-1479.
17. Buchholz TA, Shimotakahara SG, Weymuller EA Jr, et al. Neutron radiotherapy for adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1993;119:747-752.
18. Douglas JG, Laramore GE, Austin-Seymour M, et al. Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 2000;46:551-557.
19. Henderson JW, Neault RW. En bloc removal of intrinsic neoplasms of the lacrimal gland. Am J Ophthalmol 1976;82:905-909.
20. Rootman J, Lapointe JS. Tumors of the lacrimal gland. In: Rootman J, ed. Diseases of the Orbit; A Multidisciplinary Approach. Philadelphia: Lippincott; 1988:384-395.
21. Marsh JL, Wise DM, Smith M, et al. Lacrimal gland adenoid cystic carcinoma: intracranial and extracranial en bloc resection. Plast Reconstr Surg 1981;68:577-585.
22. Janecka I, Housepian E, Trokel S, et al. Surgical management of malignant tumors of the lacrimal gland. Am J Surg 1984;148:539-541.
23. Henderson JW. Past, present, and future surgical management of malignant epithelial neoplasms of the lacrimal gland. Br J Ophthalmol 1986;70:727-731.
24. Ashton N. Epithelial tumours of the lacrimal gland. Mod Probl Ophthalmol 1975;14:306-323.
25. Zimmerman LE, Sanders TE, Ackerman LV. Epithelial tumors of the lacrimal gland: prognostic and therapeutic significance of histologic types. Int Ophthalmol Clin 1962;2:337-367.
26. Wright JE, Rose GE, Garner A. Primary malignant neoplasms of the lacrimal gland. Br J Ophthalmol 1992;76:401-407.
27. Esmaeli B, Ahmadi MA, Youssef A, et al. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthalmic Plast Reconstr Surg 2004;20:22-26.
28. Bartley GB, Harris GJ. Adenoid cystic carcinoma of the lacrimal gland: Is there a cure...yet? Ophthalmic Plast Reconstr Surg 2002;18:315-318.
29. Naugle T Jr, Tepper DJ, Haik BG. Adenoid cystic carcinoma of the lacrimal gland: a case report. Ophthalmic Plast Reconstr Surg 1994;10:45-48.
30. Ni C, Cheng SC, Dryja TP, et al. Lacrimal gland tumors: a clinicopathological analysis of 160 cases. Int Ophthalmol Clin 1982;22:99-120.
31. Meldrum ML, Tse DT, Benedetto P. Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol 1998;116:315-321.
32. Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diamminedichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer 1983;51:402-407.
33. Feun LG, Wallace S, Stewart DJ, et al. Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 1984;54:794-799.
34. Lehane DE, Bryan RN, Horowitz B, et al. Intraarterial cis-platinum chemotherapy for patients with primary and metastatic brain tumors. Cancer Drug Deliv 1983;1:69-77.
35. Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver; the Northern California Oncology Group Trial. J Clin Oncol 1989;7:1646-1654.
36. Kajanti M, Rissanen P, Virkkunen P, et al. Regional intra-arterial infusion of cisplatin in primary hepatocellular carcinoma; a phase II study. Cancer 1986;58:2386-2388.
37. McKenzie Pratt RM, Betteridge TJ, Dixon P. Regional arterial cytotoxic perfusion combined with radical operation in breast cancer. Br J Surg 1963;50:833-837.
38. Stephens FO, Harker GJ, Crea P. The intraarterial infusion of chemotherapeutic agents as "basal" treatment of cancer: evidence of increased drug activity in regionally infused tissues. Aust N Z J Surg 1980;50:597-602.
39. Sessions RB, Lehane DE, Smith RJ, et al. Intra-arterial cisplatin treatment of adenoid cystic carcinoma. Arch Otolaryngol 1982;108:221-224.
40. Lee YY, Wallace S, Dimery I, et al. Intraarterial chemotherapy of head and neck tumors. AJNR Am J Neuroradiol 1986;7:343-348.
41. Arcangeli G, Nervi C, Righini R, et al. Combined radiation and drugs: the effect of intra-arterial chemotherapy followed by radiotherapy in head and neck cancer. Radiother Oncol 1983;1:101-107.
42. Suen JY, Johns ME. Chemotherapy for salivary gland cancer. Laryngoscope 1982;92:235-239.
43. Tsukuda M, Kokatsu T, Ito K, et al. Chemotherapy for recurrent adeno- and adenoid cystic carcinomas in the head and neck. J Cancer Res Clin Oncol 1993;119:756-758.
44. Schramm VL Jr, Srodes C, Myers EN. Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol 1981;107:739-741.
45. Scheel JV, Schilling V, Kastenbauer E, et al. Cisplatin intraarteriell und sequentielle Strahlentherapie; Langzeit - Ergegnisse. Laryngorhinootologie 1996;75:38-42.
46. Kaplan MJ, Johns ME, Cantrell RW. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 1986;95:165-170.
47. Venook AP, Tseng A Jr, Meyers FJ, et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 1987;5:951-955.
48. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185-200.
49. Pineau P, Buendia MA. Studies of genetic defects in hepatocellular carcinoma: recent outcomes and new challenges. J Hepatol 2000;33:152-156.
50. Finkelstein SD, Marsh W, Demetris AJ, et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 2003;37:871-879.
51. Rolston R, Sasatomi E, Hunt J, et al. Distinguishing de novo second cancer formation from tumor recurrence: mutational fingerprinting by microdissection genotyping. J Mol Diagn 2001;3:129-132.
52. Cheung O, Kandil H, Moser AJ, et al. Primary duodenal carcinoma showing divergent growth patterns as determined by microdissection-based mutational genotyping. Arch Pathol Lab Med 2003;127:861-864.
53. Sasatomi E, Finkelstein SD, Woods JD, et al. Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value. Cancer Res 2002;62:2681-2689.
54. Forrest AW. Pathologic criteria for effective management of epithelial lacrimal gland tumors. Am J Ophthalmol 1971;71:178-192.
55. American Joint Committee on Cancer: Reporting of cancer survival and end results. In: Beahrs O, Henson DE, Hutter RVP, et al, eds. Manual for Staging of Cancer. 4th ed. Philadelphia: Lippincott; 1992:11-23.
56. Finkelstein SD, Przygodzki R, Swalsky PA. Microdissection-based p53 genotyping: concepts for molecular testing. Mol Diagn 1998;3:179-191.
57. Finkelstein SD, Mohan D, Hamilton RL, et al. Microdissection-based genotyping assists discrimination of reactive gliosis from glioma. Am J Clin Pathol 2004;121:671-678.
58. Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas; Children's Cancer Group. N Engl J Med 2002;346:420-427.
59. Rubin MA. Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer. J Pathol 2001;195:80-86.
60. Cong WM, Bakker A, Swalsky PA, et al. Multiple genetic alterations involved in the tumorigenesis of human cholangiocarcinoma: a molecular genetic and clinicopathological study. J Cancer Res Clin Oncol 2001;127:187-192.
61. Miyai K, Furugen Y, Matsumoto T, et al. Loss of heterozygosity analysis in uterine cervical adenocarcinoma. Gynecol Oncol 2004;94:115-120.
62. Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR, et al. Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res 2004;64:871-875.
63. Fernando HC, Sasatomi E, Christie NA, et al. Comparison of mutational changes in involved N1 lymph nodes with those in primary tumors in stage II non-small cell lung cancer: a pilot study. J Thorac Cardiovasc Surg 2004;127:87-91.
64. Nakayama S, Nakayama K, Takebayashi Y, et al. Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy. Int J Mol Med 2003;11:621-625.
65. Park S, Kim SW, Kim SH, et al. Loss of heterozygosity in ampulla of Vater neoplasms during adenoma-carcinoma sequence. Anticancer Res 2003;23:2955-2959.
66. Ishikawa Y, Furuta R, Miyoshi T, et al. Loss of heterozygosity and the smoking index increase with decrease in differentiation of lung adenocarcinomas: etiologic implications. Cancer Lett 2002;187:47-51.
67. Jiang WW, Fujii H, Shirai T, et al. Accumulative increase of loss of heterozygosity from leukoplakia to foci of early cancerization in leukoplakia of the oral cavity. Cancer 2001;92:2349-2356.
68. Shao JY, Huang XM, Yu XJ, et al. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma. Anticancer Res 2001;21:3021-3029.
69. Diaz EM Jr, Kies MS. Chemotherapy for skull base cancers. Otolaryngol Clin North Am 2001;34:1079-1085; viii.
70. Stewart DJ, Wallace S, Feun L, et al. A phase I study of intracarotid artery infusion of cis-Diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors. Cancer Res 1982;42:2059-2062.
71. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984;2:498-504.
72. Forastiere AA, Takasugi BJ, Baker SR, et al. High-dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 1987;19:155-158.
73. Sato Y, Morita M, Takahashi HO, et al. Combined surgery, radiotherapy, and regional chemotherapy in carcinoma of the paranasal sinuses. Cancer 1970;25:571-579.
74. Lee MM, Vokes EE, Rosen A, et al. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am 1999;5:219-223.
75. Nishino H, Miyata M, Morita M, et al. Combined therapy with conservative surgery, radiotherapy, and regional chemotherapy for maxillary sinus carcinoma. Cancer 2000;89:1925-1932.
76. Goepfert H, Jesse RH, Lindberg RD. Arterial infusion and radiation therapy in the treatment of advanced cancer of the nasal cavity and paranasal sinuses. Am J Surg 1973;126:464-468.
77. Papadimitrakopoulou VA, Hong WK. Combined-modality therapy in paranasal sinus cancer. Cancer J Sci Am 1999;5:208-210.
78. Margo CE, Murtagh FR. Ocular and orbital toxicity after intracarotid cisplatin therapy [letter]. Am J Ophthalmol 1993;116:508-509.
79. Maiese K, Walker RW, Gargan R, et al. Intra-arterial cisplatin-associated optic and otic toxicity. Arch Neurol 1992;49:83-86.
80. Shimamura Y, Chikama M, Tanimoto T, et al. Optic nerve degeneration caused by supraophthalmic carotid artery infusion with cisplatin and ACNU; case report. J Neurosurg 1990;72:285-288.
81. Kupersmith MJ, Seiple WH, Holopigian K, et al. Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. Am J Ophthalmol 1992;113:435-438.
82. Lee YY, Dimery IW, Van Tassel P, et al. Superselective intra-arterial chemotherapy of advanced paranasal sinus tumors. Arch Otolaryngol Head Neck Surg 1989;115:503-511.
83. Jakobiec FA, Yeo JH, Trokel SL, et al. Combined clinical and computed tomographic diagnosis of primary lacrimal gland fossa lesions. Am J Ophthalmol 1982;94:785-807.
84. Wharton JACL, O'Donnell BA. Unusual presentations of pleomorphic adenoma and adenoid cystic carcinoma of the lacrimal gland. Aust N Z J Ophthalmol 1999;27:145-148.
85. Tellado MV, McLean IW, Specht CS, et al. Adenoid cystic carcinomas of the lacrimal gland in childhood and adolescence. Ophthalmology 1997;104:1622-1625.
86. Shields JA, Shields CL, Eagle RC Jr, et al. Adenoid cystic carcinoma developing in the nasal orbit. Am J Ophthalmol 1997;123:398-399.
87. Levartovsky S, Milstein A, Nissim F, et al. An unusual presentation of adenoid cystic carcinoma of the lacrimal gland. Ophthalmic Plast Reconstr Surg 1993;9:47-50.
88. Duke TG, Fahy GT, Brown LJR. Adenoid cystic carcinoma of the superonasal conjunctival fornix. Orbit 2000;19:31-35.
89. Henderson JW, Campell RJ, Farrow GM, et al. Orbital Tumors. 3rd ed. New York: Raven Press; 1994:323-342.
90. Kiratli H, Bilgic S. An unusual clinical course of adenoid cystic carcinoma of the lacrimal gland. Orbit 1999;18:197-201.
91. Günalp I, Gündüz K. Epithelial tumors of the lacrimal gland. Orbit 1994;13:147-154.
92. Kaur A, Harrigan MR, MeKeever PE, et al. Adenoid cystic carcinoma metastatic to the dura: report of two cases. J Neurooncol 1999;44:267-273.
93. Mohan D, Finkelstein SD, Swalsky PA, et al. Microdissection genotyping of gliomas: therapeutic and prognostic considerations. Mod Pathol 2004;17:1346-1358.
94. Marsh JW, Finkelstein SD, Demetris AJ, et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl 2003;9:664-671.
95. Williams H. Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 2000;53:165-172.
96. Mao L, Lee DJ, Tockman MS, et al. Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci U S A 1994;91:9871-9875.
97. Hunt JL, Swalsky P, Sasatomi E, et al. A microdissection and molecular genotyping assay to confirm the identity of tissue floaters in paraffin-embedded tissue blocks. Arch Pathol Lab Med 2003;127:213-217.